Rare diseases epidemiology research

Advances in Experimental Medicine and Biology

Volumn 686, Issue , 2010, Pages 17-39

  De La Paz, Manuel Posada ^a   Villaverde Hueso, Ana ^b   Alonso, Verónica ^b   János, Sándor ^b   Zurriaga, Óscar ^b   Pollán, Marina ^b   Abaitua Borda, Ignacio ^b  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^b NONE

Author keywords

Analytical epidemiology; Environmental epidemiology; Epidemiological methods; Epigenetic; Genetic epidemiology; Hypotheses generation; Risk factors

Indexed keywords

ARTICLE; CLUSTER ANALYSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; EPIDEMIOLOGICAL DATA; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC EPIDEMIOLOGY; HEALTH CARE POLICY; HUMAN; INCIDENCE; INFORMATION PROCESSING; INTERNATIONAL CLASSIFICATION OF DISEASES; MEDICAL DECISION MAKING; MEDICAL RESEARCH; METHODOLOGY; MORBIDITY; MORTALITY; OBSERVATIONAL STUDY; PATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; QUALITY ADJUSTED LIFE YEAR; QUALITY CONTROL; RARE DISEASE; CLASSIFICATION; EPIDEMIOLOGY; GENETIC EPIGENESIS; GENETICS; HEALTH SURVEY;

CAUSALITY; CLUSTER ANALYSIS; EPIDEMIOLOGIC RESEARCH DESIGN; EPIGENESIS, GENETIC; HEALTH STATUS INDICATORS; HUMANS; PREVALENCE; RARE DISEASES;

EID: 79952053398     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-90-481-9485-8_2     Document Type: Article

References (68)

1. Alison A, Motsinger-Reif AA, Reif DM, Fanelli TJ, Ritchie MD (2008) Comparison of analytical methods for genetic association studies. Genet Epidemiol 32:767-778
2. Bermejo E, Cuevas L, Grupo Periférico del ECEMC, Martínez-Frías ML (2009) Vigilancia epidemiológica de anomalías congénitas en España: Análisis de los datos del registro del ECEMC en el período 1980-2008. Bol ECEMC Rev Dismor Epidemiol V(8):4-91. [access: January 2010]. Available: Http://bvs.isciii.es/ mono/pdf/CIAC-08.pdf
3. Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P; CONSORT Group (2008) Methods and processes of the CONSORT Group: Example of an extension for trials assessing nonpharmacologic treatments. Ann Intern Med 148(4):W60-W66
4. Burton PR, Tobin MD, Hopper JL (2005) Key concepts in genetic epidemiology. Lancet 366:941-951 (Pubitemid 41265670)
5. Breslow NE, Lumley T, Ballantyne CM, Chambless LE, Kulich M (2009) Using the whole cohort in the analysis of case-cohort data. Am J Epidemiol 169(11):1398-1405
6. Bruce S, Hannula-Jouppi K, Peltonen J, Kere J, Lipsanen-NymanM(2009) Clinically distinct epigenetic subgroups in Silver-Russell syndrome: The degree of H19 hypomethylation associates with phenotype severity and genital and skeletal anomalies. J Clin Endocrinol Metab 94(2):579-587
7. Campbell MK, Elbourne DR, Altman DG; CONSORT Group (2004) CONSORT statement: Extension to cluster randomised trials. BMJ 328(7441):702-708 (Pubitemid 38393415)
8. Centers for Disease Control (CDC) (1990) Guidelines for investigating clusters of health events. MMWR 39(RR-11):1-16. [access: January 2010]. Available: Http://wonder.cdc.gov/wonder/prevguid/m0001797/m0001797.asp.
9. Commission of the European Communities (1999) Decision No 1295/1999/EC of the European Parliament and of the Council of 29 April 1999 adopting a programme of Community action on rare diseases within the framework for action in the field of public health (1999-2003). April 1999 [access: January 2010]. Available: Http://eurlex. europa.eu/pri/en/oj/dat/1999/l-155/l- 15519990622en00010005.pdf
10. Commission of the European Communities. Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions on Rare Diseases: Europe's challenges (2008) [access: January 2010]. Available: Http://ec.europa.eu/health/ph- threats/non-com/docs/rare-com-en.pdf
11. Council Recommendation of 8 June 2009 on an action in the field of rare diseases (2009/C 151/02) Official Journal of the European Union, C 151/7- C 151/10 [access: January 2010]. Available: Http://eur-lex.europa.eu/LexUriServ/ LexUriServ.do?uri=OJ: C:2009:151:0007:0010:en:PDF
12. Davey Smith G, Ebrahim S, Lewis S, Hansell AL, Palmer LJ, Burton PR (2005) Genetic epidemiology and public health: Hope, hype, and future prospects. Lancet 366(9495): 1484-1498 (Pubitemid 41483815)
13. DG Health and Consumer Protection Programme of Community action in the field of public health (2003-2008) [access: January 2010]. Available: Http://ec.europa.eu/health/ph-programme/programme-en.htm
14. DisMod II. Software developed by J. Barendregt, Department of Public Health, Erasmus University Holland, in collaboration with the WHO. [Access January 2010]. Available: http://www.who.int/healthinfo/global-burden-disease/ tools-software/en/index.html.
15. E-RARE. ERA-Net for research programs on rare diseases. http://www.e-rare.eu/
16. EUGLOREH 2007 (2009) Chapter 9.1.2 Congenital malformations. In: The Status of Health in the European Union: Towards a healthier Europe, EU Public Health Programme Project, Global Report on the Health Status in the European Union. [access: January 2010]. Available: http://www.eugloreh.it/ActionPagina- 993.do
17. EUROCAT-Cluster Advisory Service (2003) Cluster Investigation Protocols. [access: January 2010]. Available: http://www.eurocat.ulster.ac.uk/ clusterinvprot.html
18. EUROCAT (2008) EUROCAT Statistical Monitoring Protocol. http://www.eurocat.ulster. ac.uk/pubdata/Stat-Mon.html
19. EUROPLAN. The European Project for Rare Diseases National Plans Development. http://www.europlanproject.eu/
20. European Medicines Agency (EMEA) (2000) Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products [access: January 2010]. Available: Http://eur-lex.europa.eu/ LexUri- Serv/site/es/oj/2000/l-018/l-01820000122es00010005.pdf
21. European Medicines Agency (EMEA) (2002) Points to consider on the calculations and reporting of prevalence of a condition for orphan designation. London 26 Mar 2002 COMP/436/01. [access: January 2010]. Available: Http://www.ema.europa.eu/pdfs/human/comp/043601.pdf
22. Faucett WA, Hart S, Pagon RA, Neall LF, Spinella G (2008) A model program to increase translation of rare disease genetic tests: Collaboration, education, and test translation program. Genet Med 10(5):343-348 (Pubitemid 351770404)
23. Feinberg AP, Tycko B (2004) The history of cancer epigenetics. Nat Rev Cancer 4(2): 143-153 (Pubitemid 38198742)
24. Feinberg AP (2010) Genome-scale approaches to the epigenetics of common human disease. Virchows Arch 456(1):13-21
25. Foley DL, Craig JM, Morley R, Olsson CA, Dwyer T, Smith K, Saffery R (2009) Prospects for Epigenetic Epidemiology. Am J Epidemiol 169(4):389-400
26. Greenhouse JB (2009) Commentary: Cornfield, epidemiology and causality. Int J Epidemiol 38:1199-1201
27. Greenland S, Brumback B (2002) An overview of relations among causal modelling methods. Int J Epidemiol 31(5):1030-1037 (Pubitemid 35446879)
28. Håberg SE, London SJ, Stigum H, Nafstad P, Nystad W (2009) Folic acid supplements in pregnancy and early childhood respiratory health. Arch Dis Child 94:180-184.
29. Hampton T (2006) Rare disease research gets boost. JAMA 295(24):2836-2838 (Pubitemid 43974169)
30. Hennekens CH, Buring JE (1987) Epidemiology in medicine. Little, Brown and Company, Boston, MA
31. Hill AB (1965) The environment and disease: Association or causation? Proc Roy Soc Med 58:295-300
32. Hobbs CA, Hopkins SE, Simmons CJ (2001) Sources of variability in birth defects prevalence rates. Teratology 64 (Suppl 1):S8-S13
33. International Conferences on Rare Diseases and Orphan Drugs (ICORD). http://www.icord.se/
34. Ioannidis JP (2007) Genetic and molecular epidemiology. J Epidemiol Community Health 61:757-758 (Pubitemid 47311711)
35. Ioannidis JP, Boffetta P, Little J, O'Brien TR, Uitterlinden AG, Vineis P, Balding DJ, Chokkalingam A, M Dolan SM, Flanders WD, Higgins Julian PT, McCarthy MI, McDermott David H, Page Grier P, Rebbeck TR, Seminara D, Khoury MJ (2008) Assessment of cumulative evidence on genetic associations: Interim guidelines. Int J Epidemiol 37(1):120-132 (Pubitemid 351228620)
36. Jorgensen TJ, Ruczinski I, Kessing B, SmithMW, Shugart YY, Alberg AJ (2009) Hypothesisdriven candidate gene association studies: Practical design and analytical considerations. Am J Epidemiol 170(8):986-993
37. Khoury MJ, Little J, Gwinn M, Ioannidis JP (2007) On the synthesis and interpretation of consistent but weak gene-disease associations in the era of genome-wide association studies. Int J Epidemiol 36:439-445 (Pubitemid 47062866)
38. Kleinbaum DG, Kupper LL, Morggenstern H (1982) Epidemiologic Research. Principles and quantitative methods. Van Nostrand Reinhold, New York
39. Last J (2001) A dictionary of epidemiology, 4th edn. Oxford University Press, New York
40. Little J, Higgins JPT, Ioannidis JPA, Moher D, Gagnon F, von Elm E, Khoury MJ, et al (2009) STrengthening the REporting of Genetic Association Studies (STREGA) An Extension of the STROBE Statement. Plos Med 6(2):151-163.
41. Martínez-Frías ML (2007) Postmarketing analysis of medicines: Methodology and value of the Spanish case-control study and surveillance system in preventing birth defects. Drug Safety 30(4):307-316 (Pubitemid 46624530)
42. Mason CA, Kirby RS, Sever LE, Langlois PH (2005) Prevalence is preferred measures of frequency of birth defects. Birth Defects Res A Clin Mol Teratol 73(10):690-692 (Pubitemid 41572011)
43. Miettinen OS (2004) Epidemiology: quo vadis? Eur J Epidemiol 19(8):713-718 (Pubitemid 41184416)
44. Moher D, Schulz KF, Altman DG, CONSORT Group (2001) The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 357:1191-1194 (Pubitemid 32378696)
45. Murray CJ, Acharya AK (1997) Understanding DALYs (disability-adjusted life years) J Health Econ. 16(6):703-730
46. National Institutes of Health. Library National ofMedicine (2010) Medical Subject Headings. http://www.nlm.nih.gov/mesh/meshhome.html
47. Online Mendelian Inheritance in Man (OMIM): http://www.ncbi.nlm.nih.gov/ Omim/
48. Orphanet Report Series (2010) Prevalence of rare diseases: Bibliographic data. [access: June 2010]. Available: Http://www.orpha.net/orphacom/cahiers/ docs/GB/Prevalence-of-rare-diseases-by-alphabetical-list.pdf
49. ORPHANET (2010). [Access: June, 2010]: http://www.orpha.net/
50. Rare Diseases Task Force (RDTF) Working Group Coding, classification and data confidentiality: [access: January 2010]. Available: Http://www.orpha.net/ testor/cgi-bin/OTmain. php?PHPSESSID= cea107c54dc7d292c2e5775ca686dd16&UserCell=workingGroup
51. RARECARE. Surveillance of Rare Cancers in Europe. Rationale & Questions for Consensus [Access January 2010]. Available: Http://www.rarecare. eu/rarecancers/Rationales- and-questions-for-consensus-24-12-08.pdf
52. Rose G (1985) Sick individuals and sick populations. Inter J Epidemiol 14:32-38 (Pubitemid 15109489)
53. Rothman KJ, Greenland S, Lash TL (2008) Modern epidemiology. Lippincott Williams & Wilkins, Philadelphia
54. Sanderson S, Tatt ID, Higgins JP (2007) Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: A systematic review and annotated bibliography. Int J Epidemiol 36:666-676 (Pubitemid 47244573)
55. Schieppati A, Henter JI, Daina E, Aperia A (2008) Why rare diseases are an important medical and social issue. Lancet 371(9629):2039-241
56. Systematized Nomenclature of Medicine (SNOMED) http://www.ihtsdo.org/ snomed-ct/57.
57. Thomas DC (2006) Are we ready for genome-wide association studies? Cancer Epidemiol Biomarkers Prev 15:595-598
58. Vandenbroucke JP, von Elm E, Altman DG, Gø tzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M; STROBE initiative (2007) Strengthening the reporting of observational studies in epidemiology (STROBE): Explanation and elaboration. Ann Intern Med 147(8):163-194W.
59. Villaverde-Hueso A, Sánchez-Valle E, Álvarez E, Morant C, Carreira PE, Martín-Arribas MC, Gènova R, Ramírez- González A, Posada de la Paz M (2007) Estimating the Burden of Scleroderma Disease in Spain. J Rheumatol 34(11):2236-2242 (Pubitemid 350076885)
60. von Elm E, Altman D G, Egger M, Pocock SJ, Gø tzsche PC, Vandenbroucke JP for the STROBE Initiative (2008) Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. J Clin Epidemiol 61(4):344-349 (Pubitemid 351289042)
61. von Elm E, Moher D, Little J and STREGA collaboration (2009) Reporting genetic association studies: The STREGA statement. Lancet 374(9684):98-100
62. Wacholder S (2009) Nested case-control studies: Commentary. Bias in Full Cohort and Nested Case-Control Studies? Epidemiology 3:339-340
63. Washington State Department of Health (2007) Guidelines for Investigating Clusters of Chronic Disease and Adverse Birth Outcomes. [access: January 2010]. Available: http://www.doh.wa.gov/EHSPHL/Epidemiology/NICE/publications/ ClusterProtocol.pdf
64. Webb P, Bain C, Pirozzo S (2005) How long is a piece of string? Measuring diseases frequency. In: Webb P, Bain C, Pirozzo S (eds) Essential epidemiology: An introduction for students and health proffesionals. Cambridge University Press, Cambridge, pp 28-60
65. WHOFIC Network. Production of ICD-11: The overall revision process. March 2007 [access January 2010]. Available: Http://www.who.int/classifications/icd/ ICDRevision.pdf
66. Wolf SH (2008) The meaning of translational research and why it matters. JAMA 299(2): 211-213
67. World Health Organization. International Statistical Classification of Diseases and Related Health Problems 10th Revision. Version for 2006. [access: January 2010]. Available: http://www.who.int/classifications/apps/icd/ icd10online/
68. Wynne JW, Harris J, Bentley S, Stierman L (1999) California Birth Defects Monitoring Program (CBDMP). Investigating clusters of birth defects: A systematic approach. [access: January 2010]. Available: http://www.cbdmp.org/ pdf/investbdclusters.pdf